|
|
- 2016
肾母细胞瘤中ERCC1、TUBB3、TOP2A mRNA的表达及临床意义
|
Abstract:
摘要：目的 探讨核苷酸切除修复交叉互补基因(excision repair cross complementation 1, ERCC1)、3型β微管蛋白编码基因(Class Ⅲ β-tubulin, TUBB3)和DNA拓扑异构酶Ⅱα(Topoisomerase ⅡA, TOP2A)mRNA在小儿肾母细胞瘤组织中的表达及临床意义。方法 收集18例肾母细胞瘤组织标本及14例癌旁组织标本，通过分支-DNA液相芯片法检测标本中ERCC1、TUBB3、TOP2A mRNA的表达水平，并分析上述基因表达与肾母细胞瘤临床病理的关系。结果 肾母细胞瘤组织中ERCC1、TUBB3和TOP2A高表达率分别为44.4%、50.0%和66.7%，均显著高于癌旁组织的7.1%、7.1%和14.3%，差异有统计学意义(P<0.05)。ERCC1高表达率与肾母细胞瘤临床分期和病理类型有关(P<0.05)，TOP2A高表达率与肾母细胞瘤临床分期相关(P<0.05)。结论 小儿肾母细胞瘤组织中ERCC1、TUBB3和TOP2A mRNA表达高于癌旁组织，可能参与肾母细胞瘤的发生发展过程。
ABSTRACT: Objective To investigate the expression and clinical significance of excision repair cross complementation 1(ERCC1), Class Ⅲ β-tubulin(TUBB3) and topoisomerase ⅡA(TOP2A) in nephroblastoma. Methods The expression levels of ERCC1, TUBB3 and TOP2A in 18 cases of nephroblastoma tissue and 14 cases of peritumoral tissue were detected by branch-DNA liquid chip technology. The relationship of the expressions of the above genes with the clinicopathologic characteristics of nephroblastoma was analyzed. Results The high expression rates of ERCC1,TUBB3 and TOP2A in nephroblastoma tissues (44.4%，50.0%, 66.7%) were significantly higher than those in peritumoral tissues (7.1%, 7.1% and 14.3%) (P<0.05). The high expression of ERCC1 was correlated with the clinical stage and histopathologic type (P<0.05). TOP2A was correlated with the clinical stage (P<0.05). Conclusion The expressions of ERCC1, TUBB3 and TOP2A were higher in nephroblastoma than in normal renal tissue. High expressions of ERCC1, TUBB3 and TOP2A may play an important role in carcinogenesis and progression of nephroblastoma
| [1] | PRESS MF, SAUTER G, BUYSE M, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy[J]. J Clin Oncol, 2011, 29(7):859-867. |
| [2] | ETTINGER DS, AKERLEY W, BORGHAEI H, et al. Non-small cell lung cancer, version 2.2013[J]. J Natl Compr Canc Netw, 2013, 11(6):645-653. |
| [3] | BRASE JC, SCHMIDT M, FISCHBACH T, et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction[J]. Clin Cancer Res, 2010, 16(8):2391-2401. |
| [4] | DAVIDOFF AM. Wilms’ tumor[J]. Curr Opin Pediatr, 2009, 21(3):357-364. |
| [5] | NAKAMURA L, RITCHEY M. Current management of Wilms’ tumor[J]. Curr Urol Rep, 2010, 11(1):58-65. |
| [6] | TSODIKOV OV, JVANOV D,ORELLI B, et al. Structural basis for the recruitment of ERCCl-XPF to nucleotide excision repair complexes by XPA[J]. EMBO, 2007, 26(22):4768-4776. |
| [7] | ZHOU W, LIU G, PARK S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(2):491-496. |
| [8] | KOH Y, JANG B, HAN SW, et al. Expression of class Ⅲ beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer[J]. J Thorac Oncol, 2010, 5(3):320-325. |
| [9] | ZHANG HL, RUAN L, ZHENG LM, et al. Association between class Ⅲ β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis[J]. Lung Cancer, 2012, 77(1):9-15. |
| [10] | CANALES RD, LUO Y, WILLEY JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms[J]. Nat Biotechnol, 2006, 24(9):1115-1122. |
| [11] | KNUDSEN BS, ALLEN AN, MCLERRAN DF, et al. Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues[J]. J Mol Diagn, 2008, 10(2):169-176. |
| [12] | PASTORE G, ZNAOR A, SPREAFICO F, et al. Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project[J]. Eur J Cancer, 2006, 42(13):2103-2114. |
| [13] | SAEBO M, SKJELBRED CF, NEXO BA，et al. Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas[J]. BMC Cancer, 2006, 16(6):208-215. |
| [14] | OLAUSSEN KA, DUNANT A, FOURET P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10):983-991. |
| [15] | VILMAR A, GARCIA-FONCILLAS J, HUARRIZ M, et al. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC[J]. Lung Cancer, 2012, 75(3):306-312. |
| [16] | FAUTREL A, ANDRIEUX L, MUSSO O, et al. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma[J]. J Hepatol, 2005, 43(2):288-293. |
| [17] | O’GRADY S, FINN SP, CUFFE S, et al. The role of DNA repair pathways in cisplatin resistant lung cancer[J]. Cancer Treat Rev, 2014, 40(10):1161-1170. |
